HSBC Holdings
HAE icon

HSBC Holdings’s Haemonetics HAE Stock Holding History

HSBC Holdings’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100
Closed -$7.81K – 3133
2024
Q4 		$7.81K Buy
+100
New +$8.03K ﹤0.01% 3074
2024
Q2 		– Sell
-27,600
Closed -$2.36M – 3035
2024
Q1 		$2.36M Buy
27,600
+10,300
+60% +$808K ﹤0.01% 1395
2023
Q4 		$1.49M Buy
17,300
+13,200
+322% +$1.14M ﹤0.01% 1609
2023
Q3 		$373K Buy
+4,100
New +$366K ﹤0.01% 2099
2023
Q2 		– Sell
-23,800
Closed -$1.96M – 2639
2023
Q1 		$1.96M Sell
23,800
-34,300
-59% -$2.78M ﹤0.01% 1521
2022
Q4 		$4.52M Buy
58,100
+56,300
+3,128% +$4.53M 0.01% 1296
2022
Q3 		$135K Buy
+1,800
New +$129K ﹤0.01% 2713
2021
Q4 		– Sell
-39,500
Closed -$2.79M – 3294
2021
Q3 		$2.79M Hold
39,500
– – ﹤0.01% 1394
2021
Q2 		$2.63M Buy
+39,500
New +$2.8M ﹤0.01% 1333

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's HAE Position: Q2 2026 in Review

HSBC Holdings sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 37,256 shares — an estimated $2.1M sold.

HSBC Holdings first reported a position in HAE in Q4 2016 and held it in 31 quarters. The position peaked at $22.8M in Q2 2018. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • HSBC Holdings reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
  • HSBC Holdings sold 37,256 Haemonetics shares in Q2 2026, an estimated $2.1M.
  • HSBC Holdings first reported a position in Haemonetics in Q4 2016 and held it in 31 quarters.
  • HSBC Holdings's Haemonetics position peaked at $22.8M in Q2 2018.
  • 330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.